Telesis Bio Hit on Prelim 4th Quarter 2023 Financial Results

 

• Total revenue for the fourth quarter of 2023 is expected to be $7.0 million, a 26.3% reduction from $9.5 million for the same period in 2022 due primarily to capital spending weakness in end markets and the resulting mix-shift toward lower-priced BioXp 3250 instruments. Total revenue, excluding BioXp instrument sales and discontinued BioFoundry Services operations, were $20.9 million for the full fiscal-year period, an increase of 12.4% compared to $18.6 million for the same categories in the prior year period.

https://www.globenewswire.com/news-release/2024/02/26/2835202/0/en/Telesis-Bio-Announces-Select-Preliminary-Fourth-Quarter-2023-Financial-Results.html